These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8340790)

  • 1. Multiple sclerosis: from immunogenetics to immunotherapy.
    Oksenberg JR; Panzara MA; Steinman L
    J Neurol Sci; 1993 Apr; 115 Suppl():S29-37. PubMed ID: 8340790
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis: MHC associations and therapeutic implications.
    Holmes S; Friese MA; Siebold C; Jones EY; Bell J; Fugger L
    Expert Rev Mol Med; 2005 Feb; 7(3):1-17. PubMed ID: 15710050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease].
    Miller A; Weiner HL; Abramsky O
    Harefuah; 1992 Aug; 123(3-4):110-5. PubMed ID: 1516860
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of the MHC and T-cell receptor in susceptibility to multiple sclerosis.
    Oksenberg JR; Steinman L
    Curr Opin Immunol; 1989-1990 Apr; 2(4):619-21. PubMed ID: 2700905
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding multiple sclerosis: new immunologic insights and prospects for specific therapy.
    Ransohoff RM
    Compr Ther; 1991 Nov; 17(11):3-6. PubMed ID: 1799959
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell receptor germline genes and multiple sclerosis susceptibility: an unfinished tale.
    Ransohoff RM
    Neurology; 1992 Apr; 42(4):714-8. PubMed ID: 1373478
    [No Abstract]   [Full Text] [Related]  

  • 7. T cell receptor peptides for the vaccination therapy of multiple sclerosis.
    Brocke S
    Ernst Schering Res Found Workshop; 2000; (30):167-79. PubMed ID: 10943323
    [No Abstract]   [Full Text] [Related]  

  • 8. Tweaking T cells with altered antigens.
    McCarthy M
    Lancet; 1996 Feb; 347(8999):460. PubMed ID: 8618493
    [No Abstract]   [Full Text] [Related]  

  • 9. Designing rational therapies for multiple sclerosis.
    Steinman L; Conlon P
    Biotechnology (N Y); 1995 Feb; 13(2):118-20. PubMed ID: 9678929
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic factors in multiple sclerosis.
    Oksenberg JR; Begovich AB; Erlich HA; Steinman L
    JAMA; 1993 Nov; 270(19):2362-9. PubMed ID: 8230601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis.
    Zipp F; Kerschensteiner M; Dornmair K; Malotka J; Schmidt S; Bender A; Giegerich G; de Waal Malefyt R; Wekerle H; Hohlfeld R
    Brain; 1998 Aug; 121 ( Pt 8)():1395-407. PubMed ID: 9712003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where to hit MS.
    Lancet; 1991 Mar; 337(8744):765-7. PubMed ID: 1706449
    [No Abstract]   [Full Text] [Related]  

  • 13. [Susceptibility to multiple sclerosis and T-lymphocyte receptor genes. A synthetic review].
    Bongioanni P; Fioretti C; Meucci G
    Minerva Med; 1995 Dec; 86(12):543-9. PubMed ID: 8684681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen specific immunotherapy of multiple sclerosis.
    Steinman L; Conlon P
    J Clin Immunol; 2001 Mar; 21(2):93-8. PubMed ID: 11332658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coming of age for antigen-specific therapy of multiple sclerosis.
    Steinman L
    Eur J Neurol; 2006 Aug; 13(8):793-4. PubMed ID: 16879287
    [No Abstract]   [Full Text] [Related]  

  • 16. Inducible expression of antigens in plants: a study focused on peptides related to multiple sclerosis immunotherapy.
    Arevalo-Villalobos JI; Govea-Alonso DO; Bañuelos-Hernández B; González-Ortega O; Zarazúa S; Rosales-Mendoza S
    J Biotechnol; 2020 Jul; 318():51-56. PubMed ID: 32387449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
    Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
    Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic intervention in autoimmunity.
    Tisch R; Yang XD; McDevitt HO
    Behring Inst Mitt; 1994 Jul; (94):171-8. PubMed ID: 7998910
    [No Abstract]   [Full Text] [Related]  

  • 19. Modelling multiple sclerosis.
    Ebers G
    Nat Genet; 1999 Nov; 23(3):258-9. PubMed ID: 10545935
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunopathogenic mechanisms in experimental allergic encephalomyelitis.
    Kálmán B; Lublin FD
    Curr Opin Neurol Neurosurg; 1993 Apr; 6(2):182-8. PubMed ID: 7683223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.